

Annex A: Antibigram for the Public Hospitals of Mauritius

For the Year 2017

For general in-patients

% of isolates that are susceptible to the given antibiotic	Penicillin	Ampicillin	Oxacillin	Ceftriaxone	Piperacillin-tazobactam	Meropenem	Gentamicin	Amikacin	Ciprofloxacin	Erythromycin	Tetracycline	Colistin	Vancomycin
Gram negatives													
<i>Escherichia coli</i>				44	76	95	63	81	40			100	
<i>Klebsiella sp.</i>				38	60	85	57	73	48			98	
<i>Pseudomonas aeruginosa</i> [#]					74	54	47	56	42			100	
<i>Proteus sp.</i>				58	100	97	55	69	76				
<i>Acinetobacter sp.</i>				2	19	26	23	43	17			100	
Gram positives													
<i>Staphylococcus aureus</i>	4		53							73	70		100
<i>Enterococcus sp.</i>		89								22	20		100

[#] - 55% of *Pseudomonas aeruginosa* were susceptible to ceftazidime. Data are from organisms isolated in 2017. Sample size is limited (n = 106 to 155).

Reference: Dr. M. Issack. Samples were collected and analyzed at the Central Health Laboratory, Victoria Hospital, and at Dr. A. G. Jeetoo Hospital

For outpatients and Accident and Emergency patients

% of isolates that are susceptible to the given antibiotic	Penicillin	Ampicillin	Oxacillin	Co-amoxiclav	Ceftriaxone	Levofloxacin	Clarithromycin	Tetracycline	Co-trimoxazole	Vancomycin
Gram negatives										
<i>Haemophilus influenzae</i>		50		100	97	100	88			
<i>Salmonella sp. (non-typhi)</i>					99	98			98	
<i>Campylobacter sp.</i>						46	100			
Gram positives										
<i>Enterococcus sp.</i> [#]		100					9	18		100
<i>Streptococcus pneumoniae</i>	97 / 56*				95	97	62	79		
Group A <i>Streptococcus</i> [#]	100						94	27		
Group B <i>Streptococcus</i> [#]		100						19		100
<i>Staphylococcus saprophyticus</i> [#]			100				60	80		100

[#] - These organisms were isolated in 2017; the other organisms were isolated in 2019. * - 97% for MIC ≤ 2 $\mu\text{g/mL}$; 56% for MIC ≤ 0.06 $\mu\text{g/mL}$. Susceptibilities for pneumococci were based mostly on samples collected from ear swabs in children. 55% of Enterobacteriaceae were susceptible to co-trimoxazole and 80% of Enterobacteriaceae were susceptible to pivmecillinam. Sample size is limited (n = 5 to 315).

For ICU patients

% of isolates that are susceptible to the given antibiotic	Co-amoxiclav	Cefotaxime	Ceftazidime	Piperacillin-tazobactam	Meropenem	Gentamicin	Amikacin	Ciprofloxacin	Colistin	Co-trimoxazole
<i>Escherichia coli</i>	23	23		87	100	65	97	32	100	35
<i>Klebsiella sp.</i>	24	22		73	78	45	74	36	100	37
<i>Pseudomonas aeruginosa</i>			59	60	45	56	57	51	100	
<i>Proteus sp.</i>	60	20		100	97	23	50	63		20
<i>Acinetobacter sp.</i>	0.5	0.5		10	13	14	28	9	100	20
<i>Enterobacter sp.</i>		59		95	100	82	95	77	100	86
<i>Serratia sp.</i>		52		96	96	48	65	57		57
<i>Stenotrophomonas maltophilia</i>	10	6		65		39	42	94	52	90

Based on endotracheal cultures collected in 2017. Sample size is limited (n = 22 to 208).

Reference: Dr. M. Issack. Samples were collected and analyzed at the Central Health Laboratory, Victoria Hospital, and at Dr. A. G. Jeetoo Hospital